Results 71 to 80 of about 2,116 (170)

Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study

Dermatology and Therapy
Introduction Evaluating the real-world effectiveness, safety, and tolerability of targeted biologic and non-biologic therapies in patients with atopic dermatitis (AD) treated in routine clinical practice remains crucial.
Tiago Torres, Jensen Yeung, Vimal H. Prajapati, Simone Ribero, Anna Balato, Angelo Valerio Marzano, Maria João Cruz, Maria João Paiva Lopes, Elizabeth Lazaridou, Jose-Manuel Carrascosa, José Miguel Alvarenga, Pedro Farinha, Bruno Duarte, Monica Munera-Campos, Siddhartha Sood, Brian D. Rankin, Michela Ortoncelli, Stefano Caccavale, Silvia Mariel Ferrucci, Gilberto Pires Rosa, Athina Ioanna Daponte, Gianmarco Silvi, Ketty Peris, Niccolò Gori, Francesca Prignano, Antonio Kolios, Pedro Herranz, Stamatios Gregoriou, Natalia Rompoti, Spyridon Gkalpakiotis, Andrea Chiricozzi   +30 more
doaj   +1 more source

Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis

Frontiers in Medicine
IntroductionAtopic dermatitis (AD) is a chronic inflammatory skin condition affecting 5%−20% of children and 2%−10% of adults worldwide. Treatment for moderate-to-severe AD includes biologics like dupilumab, tralokinumab, lebrikizumab, and JAK inhibitors
Rose Alraddadi, Rose Alraddadi, Mulham Kalantan, Mulham Kalantan, Yara Aljefri, Yara Aljefri, Hadeel Maaddawi, Abdulrahman Alsamadani, Abdulrahman Alsamadani, Athoub Kadasa, Athoub Kadasa, Abdulrahman Softah, Abdulrahman Softah, Baraa Tabbakh, Baraa Tabbakh, Rahaf Alturkistani, Abdulhadi Jfri, Abdulhadi Jfri, Abdulhadi Jfri   +18 more
doaj   +1 more source

Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies

Antibodies
Background: Head and neck dermatitis (HND) represents a challenging phenotype of atopic dermatitis (AD), often showing suboptimal response or paradoxical worsening during biologic therapy.
Giuseppe Lauletta, Cataldo Patruno, Claudio Brescia, Andrea Cosenza, Carolina D’Elia, Valentina Ventura, Emanuela Martina, Maddalena Napolitano   +7 more
doaj   +1 more source

Improvement of Dupilumab‐Induced Psoriasiform Eruption Following a Switch to Tralokinumab

JEADV Clinical Practice
Biologic therapies have transformed the management of atopic dermatitis (AD) and prurigo nodularis (PN), yet paradoxical adverse events such as dupilumab‐induced psoriasiform eruption (DPE) are increasingly recognized.
Masato Mizuashi, Yoshinori Sasaki
doaj   +1 more source

Use of Tralokinumab in the Management of Bullous Pemphigoid

SKIN The Journal of Cutaneous Medicine
A 78-year-old female with a history of asthma and depression presented with several months of generalized pruritus and tense blisters involving the trunk and extremities. She was previously diagnosed with bullous pemphigoid by an allergist based on clinical findings and positive indirect immunofluorescence and had been treated with prednisone and ...
Emily Tocco, Margaret Mercante, Diego Ruiz Dasilva   +2 more
openaire   +1 more source

[Pharmacoeconomic Comparison Between Dupilumab and Tralokinumab for the Treatment of Atopic Dermatitis in Italy: A Cost-per-Responder Analysis] [PDF]

OBJECTIVE: A cost-per-responder model was developed to compare the pharmacoeconomic value of dupilumab and tralokinumab, in combination with topical corticosteroids (TCS), for treating atopic dermatitis (AD) in Italy.METHODS: An indirect treatment ...
Povero, Massimiliano, Castello, Luca, Gisondi, Paolo, Chiricozzi, Andrea, Pani, Marcello, Pedone, Maria Paola, Noonan, Kerry, Wang, Zhixiao, Di Turi, Roberta   +8 more
core   +1 more source

Effect of tralokinumab on moderate-to-severe atopic dermatitis in patients with atopic comorbidities

Background: Atopic dermatitis (AD) is known to be associated with other atopic comorbidities that all involve type 2 immune dysregulation. Tralokinumab is a monoclonal antibody that specifically targets interleukin-13.
Paller, Amy S., Geng, Bob, Thyssen, Jacob P., Boguniewicz, Mark, Soong, Weily, Schneider, Shannon, Wollenberg, Andreas, Bennike, Niels   +7 more
core   +1 more source

Efficacy and Safety of Targeted Systemic Therapies in Head and Neck Atopic Dermatitis: A Systematic Review and Meta‐Analysis

Dermatologic Therapy
Background A distinctive and difficult phenotype, head and neck atopic dermatitis (AD) is linked to a higher disease burden and inconsistent treatment response.
Maha Mohammed Alkharisi, Abdullah Mohammed Almeziny, Raghad Saud AlOubili, Fahad Khalid Almalik, Mishari Tariq Alrubaiaan, Abdulaziz Abdullah Almohanna, Mohammed Salem Alshehri, Alanoud Alsalman, Fares Alkhayal   +8 more
doaj   +1 more source

Correction to: Tralokinumab: First Approval [PDF]

Drugs, 2021
openaire   +1 more source

Development of a psoriatic arthritis – like presentation under anti – IL-13 therapy with tralokinumab for atopic dermatitis

ObjectivesDual blockade of IL-4 and IL-13 in atopic dermatitis (AD) has been associated with activation of the IL-23/IL-17 axis, potentially leading to paradoxical psoriasis and psoriatic arthritis (PsA)-like presentation.
Di Matteo, Andrea, Kirkham, Bruce, Macleod, Tom, Lee, Sook Yan, Pink, Andrew, Marzo-Ortega, Helena, Blee, Ilona, Smith, Catherine; id_orcid, McGonagle, Dennis G., Woolf, Rick, De Marco, Gabriele, Palmer, Timothy, Meridor, Katya, Laws, Philip, Rowbotham, Emma, Abacar, Kerem, Freeston, Jane E.   +16 more
core   +1 more source